Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fulvestrant plus Anlotinib in HR+/HER2- metastatic breast cancer with FGFR mutation
NCT04936295Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Jun 2021
- Primary completion
- Jun 2023
- Countries
- 1
01
Overview
Phase 2, open-label trial of anlotinib in breast cancer, sponsored by Sun Yat-sen University. Primary endpoint: Clinical Benefit Rate at 24 weeks. Status: unknown.
02
Drugs
anlotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04936295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04936295.